Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Colagrossi, Luna; Hermans, Lucas; Salpini, Romina; Di Carlo, Domenico; Pas, Suzan; Alvarez, Marta; Ben-Ari, Ziv; Boland, Greet; Bruzzone, Bianca; Coppola, Nicola; Seguin-Devaux, Carole; Dyda, Tomasz; Garcia, Federico; Kaiser, Rolf; Kose, ŞÜKRAN; Krarup, Henrik; Lazarevic, Ivana; Lunar, Maja; Maylin, Sarah; Micheli, Valeria; Mor, Orna; Paraschiv, Simona; Paraskevis, Dimitros; Poljak, Mario; Puchhammer-Stoeckl, Elisabeth; Simon, Francois; Stanojevic, Maja; Stene-Johansen, Kathrine; Tihic, Nijaz; Trimoulet, Pascale; Verheyen, Jens; Vince, Adriana; Lepej, Snjezana; Weis, Nina; Yalcinkaya, Tulay; Boucher, Charles; Wensing, Annemarie; Perno, Carlo; Svicher, Valentina

doi:10.1186/s12879-018-3161-2

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Colagrossi L., Hermans L. E., Salpini R., Di Carlo D., Pas S. D., Alvarez M., ...Daha Fazla

BMC INFECTIOUS DISEASES, cilt.18, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 18
Basım Tarihi: 2018
Doi Numarası: 10.1186/s12879-018-3161-2
Dergi Adı: BMC INFECTIOUS DISEASES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: HBV, HBsAg, Immune-escape, Stop-codons, Drug-resistance
Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Background: HBsAg immune escape mutations can favor HBV-transmission also in vaccinated individuals, promote immunosuppression-driven HBV-reactivation, and increase fitness of drug-resistant strains. Stop-codons can enhance HBV oncogenic-properties. Furthermore, as a consequence of the overlapping structure of HBV genome, some immune-escape mutations or stop-codons in HBsAg can derive from drug-resistance mutations in RT. This study is aimed at gaining insight in prevalence and characteristics of immune-associated escape mutations, and stop-codons in HBsAg in chronically HBV-infected patients experiencing nucleos(t)side analogues (NA) in Europe.